Tackling oxaliplatin drug resistance in colorectal cancer by developing a novel bifunctional prodrug

Details

Acquired drug resistance is a considerable problem for the treatment of colorectal cancer (CRC), of which oxaliplatin is a key component, with little improvement in the ~65% 5-year survival rate over the past 25 years. Modulation of resistance pathway component expression can maintain tumour drug sensitivity during multiple cycles of treatment, minimising chances of the tumour becoming resistant, and one would ideally want to administer the modulator specifically to the tumour at the same time as the drug. In preliminary cell-based studies we have identified compounds that can reduce resistance to oxaliplatin. We have previously demonstrated that a matrix-metalloproteinase 1 (MT1-MMP) activated peptide-based prodrug can differentially release a drug payload in a CRC xenograft model, and this prodrug platform has flexibility to be applied to other payloads.

Aim

To develop a bifunctional MT1-MMP-activated peptide prodrug which will minimise acquisition of resistance and improve efficacy of oxaliplatin in CRC patients.

Focus

Design and development of a prodrug incorporating oxaliplatin and a modulator of the resistance-causing survivin, LQZ-7I, with optimisation of formulation for intravenous administration. Following confirmation of differential tumour release in ex vivo studies, in vitro and in vivo proof-of-concept in CRC resistance models will be evaluated.

Who should apply

Applicants with a passion for medicinal and/or synthetic chemistry, and cancer drug discovery. Candidates should have, or expect to obtain, a first or good upper second-class degree (or non-UK equivalent) in a chemistry-based subject or an appropriate Master’s degree qualification. We are looking for applicants with evidence of laboratory experience in organic or medicinal chemistry (e.g. a significant research project), with some experience of drug analysis and/or cell-free or in vitro screening assays.

How to apply

Formal applications can be submitted via the University of Bradford web site; applicants will need to register an account, select ‘Postgraduate Research’ as the course and then use the keywords ‘cancer therapeutics’. Applicants should then specify the project title in the ‘Research Proposal’ section.

Enquiries

For informal enquiries, please contact s.d.shnyder@bradford.ac.uk.

For further information about the Institute of Cancer Therapeutics Doctoral Training Centre, please contact r.a.falconer1@bradford.ac.uk, or take a look at our website.

About the University of Bradford

Bradford is a research-active University supporting the highest-quality research. We excel in applying our research to benefit our stakeholders by working with employers and organisations world-wide across the private, public, voluntary and community sectors and actively encourage and support our postgraduate researchers to engage in research and business development activities.

Positive Action Statement

At the University of Bradford our vision is a world of inclusion and equality of opportunity, where people want to, and can, make a difference. We place equality and diversity, inclusion, and a commitment to social mobility at the centre of our mission and ethos. In working to make a difference we are committed to addressing systemic inequality and disadvantages experienced by Black, Asian and Minority Ethnic staff and students.

Under sections 158-159 of the Equality Act 2010, positive action can be taken where protected group members are under-represented. At Bradford, our data show that people from Black, Asian, and Minority Ethnic groups who are UK nationals are significantly under-represented at the postgraduate researcher level.

These are lawful measures designed to address systemic and structural issues which result in the under-representation of Black, Asian, and Minority Ethnic students in PGR studies.